Glial tumors are an important clinical problem of both adults and children. The development of successful strategies for the prevention and treatment of these tumors has been elusive, in part as a result of our inability to properly classify these tumors as homogeneous biological entities. The development of markers which provide insights into pathogenesis, enhance patient management, allow for accurate prognostication, facilitate the effective grouping of patients for treatment and treatment evaluation is a central goal of clinical oncology. Cancer is the composite of pathologic behaviors that constitute what we recognize clinically as malignancy. We believe that the panoply of biologic activities that distinguish a tumor cell from its corresponding normal cell type is best explained by thinking of this composite as originating not only in specific genetic alterations that modify a particular biologic pathway, but also as the result of the cell mimicking the behavior of an embryonic cell and expressing some of those cellular characteristics that are both physiologic and appropriate for a cell type that exists during the normal ontogenesis of the lineage in which a particular tumor arises. This hypothesis is the foundation upon which our approach to the development of new tumor markers has been built. In this application we have proposed two different strategies for identifying new glial tumor markers: screening for genes that are differentially expressed in different situations thought to contrast various biologic features of pathologic significance (e.g. invasive vs. non-invasive) or screening for genomic regions that are either deleted or amplified in specific subgroups of glial tumors. In these experiments we will use state-of-the-art technologies including subtractive hybridization cloning, differential display of mRNA, and comparative genomic hybridization. We anticipate that candidate markers will be readily identified. To properly characterize and develop these candidates as effective tumor markers we have identified one possible algorithm, and we have identified selected reagents that can be efficaciously evaluated as part of the Glial Tumor Network's activities to characterize specific markers. These reagents include the pathologic specimens of entire cadres of glial tumor patients homogeneously-treated on previous therapeutic protocols at UCSF and patients participating in a large epidemiological study of brain tumors in Northern California. For all these patients computerized databases of information exist that will facilitate the critical evaluation of individual markers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA064898-04S1
Application #
6021625
Study Section
Special Emphasis Panel (SRC (90))
Program Officer
Jacobson, James W
Project Start
1995-03-15
Project End
2000-11-30
Budget Start
1997-12-01
Budget End
2000-11-30
Support Year
4
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Hirose, Yuichi; Aldape, Kenneth D; Chang, Susan et al. (2003) Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet 142:1-7
Kuriyama, Hiroko; Lamborn, Kathleen R; O'Fallon, Judith R et al. (2002) Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro Oncol 4:179-86
Hirose, Y; Aldape, K; Bollen, A et al. (2001) Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. Am J Pathol 158:1137-43
Hirose, Y; Aldape, K; Takahashi, M et al. (2001) Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn 3:62-7
Burger, P C; Minn, A Y; Smith, J S et al. (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842-53
Burger, P C; Pearl, D K; Aldape, K et al. (2001) Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60:1099-104
Kunwar, S; Mohapatra, G; Bollen, A et al. (2001) Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 61:7683-8
Hernandez, M; Andres-Barquin, P J; Israel, M A (2000) Assignment of the ectodermal-neural cortex 1 gene (Enc1) to mouse chromosome band 13D1 by fluorescence in situ hybridization. Cytogenet Cell Genet 89:158-9
Shu, H K; Julin, C M; Furman, F et al. (2000) Overexpression of E2F1 in glioma-derived cell lines induces a p53-independent apoptosis that is further enhanced by ionizing radiation. Neuro Oncol 2:16-21
Russo, C; Pellarin, M; Tingby, O et al. (1999) Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86:331-9

Showing the most recent 10 out of 29 publications